When a sample is sent for Afirma testing, it is first run through initial classifiers to identify if the sample contains parathyroid origin cells or rare neoplasms and lesions with >95% risk of malignancy (strong driver mutations), such as RET mutations causing medullary thyroid cancer, BRAF, and RET:PTC fusion. The gene discussed is RET; the disease is neoplasm.